When was Locus Biosciences founded?

Locus Biosciences was founded in 2015 and raised its 1st funding round 1 year after it was founded.

Where is Locus Biosciences located?

Locus Biosciences is headquartered in Raleigh, United States. It is registered at Morrisville, North Carolina.

How many employees does Locus Biosciences have?

As of Aug 31, 2026, the latest employee count at Locus Biosciences is 55.

Is Locus Biosciences a funded company?

Locus Biosciences is a funded company, having raised a total of $67.3M across 12 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Feb 05, 2016.

When was the latest funding round of Locus Biosciences?

Locus Biosciences' latest funding was a $***** Grant (prize money) round on Jan 23, 2024, with participation from 1 investor. Its primary sector is Infectious Diseases. In United States, the Infectious Diseases sector has seen $881M in funding in 2026 to date.

Where does Locus Biosciences rank among its competitors?

Locus Biosciences ranks 9th amongst 344 active competitors, of which 137 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was eGenesis, which secured $14M in Aug, 2026.

Who are the top competitors of Locus Biosciences?

Locus Biosciences' top competitors include Beam Therapeutics, Spero Therapeutics and Intellia Therapeutics. Among them, eGenesis secured the most recent funding round in August, 2026.

Locus Biosciences - 2026 Company Profile, Team, Funding & Competitors

Locus Biosciences is a series B company based in Raleigh (United States), founded in 2015 by Dave Ousterout, Chase Beisel and Charles Gersbach. It operates as a Developer of therapeutics for infectious disease and inflammatory indications. Locus Biosciences has raised $67.3M in funding from investors like Illumina, Tencent and Viking Global Investors. The company has 344 active competitors, including 137 funded and 58 that have exited. Its top competitors include companies like Beam Therapeutics, Spero Therapeutics and Intellia Therapeutics.

Company Details

Developer of therapeutics for infectious disease and inflammatory indications. The company has developed a platform to design and deliver custom CRISPR-Cas systems directly to specific bacteria and enables the development of antimicrobials for infectious diseases.

Website: www.locus-bio.com/
Social
Email ID: *****@locus-bio.com
Registered Address: Morrisville, North Carolina

Key Metrics

Founded Year

2015

Location

Raleigh, United States

Stage

Series B

Total Funding

$67.3M in 12 rounds

Latest Funding Round

Grant (prize money), Jan 23, 2024, $*****

Investors

Illumina & 14 more

Ranked

9^th among 344 active competitors

Employee Count

55 as on Aug 31, 2026

Investment & Acquisitions

EpiBiome

Similar Companies

Beam Therapeutics & 416 more

View Locus Biosciences' full profile

Locus Biosciences is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
LOCUS BIOSCIENCES, INC CIN: 474084065 , United States, Active		-	48 (As on Dec 31, 2024)	-

Locus Biosciences has raised a total funding of $67.3M over 12 rounds. Its first funding round was on Feb 05, 2016. Its latest funding round was a Grant (prize money) round on Jan 23, 2024 for $*****. 1 investor participated in its latest round. Locus Biosciences has 15 institutional investors.

Here is the list of recent funding rounds of Locus Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 23, 2024	1374126	Grant (prize money)	3562452	1562956	5607342	7508477
May 18, 2022	9598718	Series B	9895027	5012187	5681759	Artis Ventures & 1 more
Oct 20, 2021	5836690	Conventional Debt	3010221	4301049	1583182	Hercules Capital

Access funding benchmarks and valuations. Sign up today!

View details of Locus Biosciences's funding rounds and investors

The founders of Locus Biosciences are Dave Ousterout, Chase Beisel and Charles Gersbach.

Here are the details of Locus Biosciences' key team members:

Dave Ousterout: Co-Founder & CTO of Locus Biosciences and founder of 1 other company.
Contact Info: 1 email address
Chase Beisel: Co-Founder of Locus Biosciences and founder of 1 other company.
Charles Gersbach: Co-Founder of Locus Biosciences.

View details of Locus Biosciences's Founder profiles and Board Members

Locus Biosciences' employee count trend

Locus Biosciences has 55 employees as of Aug 26. Here is Locus Biosciences's employee count trend over the years:

Employee count trend for Locus Biosciences

Uncover Locus Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Locus Biosciences include Beam Therapeutics, Spero Therapeutics and Intellia Therapeutics. Here is the list of Top 10 competitors of Locus Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Beam Therapeutics 2017, Cambridge (United States), Public	Developer of gene therapy using CRISPR base editing to treat diseases	$222M	Redmile Group, Cormorant-asset & 16 others	70/100
2nd	Spero Therapeutics 2013, Cambridge (United States), Public	Developer of therapeutics for drug-resistant bacterial infections	$115M	Atlas Venture, Partners Health Care Innovation ... & 16 others	70/100
3rd	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases	$85M	Atlas Venture, Novartis & 10 others	66/100
4th	Verve 2018, Cambridge (United States), Acquired	Developer of gene-editing therapies for treating coronary artery disease	$216M	Google Ventures, Wellington & 14 others	65/100
5th	eGenesis 2015, Cambridge (United States), Series D	Developer of a gene transplantation platform for humanizing pig cells	$495M	Monashee Investment Management, Farallon Capital Management ... & 31 others	65/100
6th	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, Decheng Capital & 34 others	65/100
7th	Scribe Therapeutics 2018, Alameda (United States), Public	Developer of a gene-editing platform using CRISPR technology	$120M	Avoro Capital, Andreessen Horowitz & 7 others	65/100
8th	Metagenomi 2016, Berkeley (United States), Public	Digital gene editing technologies for drug development	$376M	Humboldt Fund, RA Capital Management & 22 others	64/100
9th	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Artis Ventures, Hercules Capital & 13 others	64/100
10th	Prime Medicine 2019, Cambridge (United States), Public	Developer of genetic therapies for a wide range of diseases	$315M	T. Rowe Price, Redmile Group & 10 others	63/100